Placeholder Banner

BIO Applauds FDA Action on AquAdvantage® Salmon

March 8, 2019
Media Contact
BIO logo
202.747.1281

Washington, D.C. (March 8, 2019) – The Biotechnology Innovation Organization (BIO) released the following statement on the action taken today by the U.S. Food & Drug Administration (FDA) which will allow AquaBounty Technologies, an American company, to commercialize its genetically engineered AquAdvantage® Salmon in the U.S. market.

“BIO applauds today’s announcement by FDA, and while long overdue, this milestone paves the way for future innovations that contribute to a more sustainable food supply for a growing world population and lessen the impact on our environment.

“Going forward, BIO will continue to work with FDA to support greater clarity in the regulatory process and an efficient, predictable pathway to product approval. By implementing a transparent, science-based and risk-appropriate regulatory path, the United States and American companies can lead the way in developing biology-driven solutions to society’s biggest challenges.”

The AquAdvantage® Salmon was developed by Massachusetts-based AquaBounty Technologies, a BIO member. It is genetically engineered to reach its market weight in half the time of conventionally raised salmon while using 25 percent less food, thus contributing to more sustainable aquaculture systems.

 

###

 

Discover More
Washington, D.C. (December 19, 2019) – The Biotechnology Innovation Organization (BIO) today released the following statement in response to EPA finalizing rules on renewable volume obligations for 2020 and SRE reallocation: “Unfortunately, this…
Washington, D.C. (December 17, 2019) – A rider to the FY2020 Agriculture Appropriations Bill will direct the bioengineered AquAdvantage salmon to carry additional labeling to distinguish it from conventionally raised Atlantic salmon. This could be…
“What has set the U.S. biotech sector apart has been thoughtful, bipartisan public policy approaches that create a favorable climate in which to undertake the lengthy and risky job of investing in and developing the next biotech breakthroughs.”